¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, ÀûÀÀÁõº°, À¯Åë ä³Îº°, Áö¿ªº°
Chronic Kidney Disease Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography
»óǰÄÚµå : 1672647
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,165,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,590,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,701,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀåÀº 2025³â¿¡ 159¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 230¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 5.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 159¾ï 2,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR: 5.40% 2032³â °¡Ä¡ ¿¹Ãø 230¾ï 2,000¸¸ ´Þ·¯
µµÇ¥. 2025³â Áö¿ªº° ¸¸¼º½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%)
Chronic Kidney Disease Drugs Market-IMG1

¼¼°è ¸¸¼º ½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº Àü ¼¼°è ½ÅÀåÁúȯ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ¸¸¼ºÄáÆÏº´(CKD)Àº ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ½ÅÀå ±â´ÉÀÌ Á¡Â÷ÀûÀ¸·Î ÀúÇϵǴ °ÍÀ» ¸»Çϸç, CKD¸¦ Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡ÇÏ¸é °á±¹ ½ÅºÎÀüÀ̳ª ¸»±â ½ÅÀåÁúȯÀ¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, CKDÀÇ ÀϹÝÀûÀÎ ¿øÀÎÀ¸·Î´Â ´ç´¢º´, °íÇ÷¾Ð, »ç±¸Ã¼½Å¿°, ´Ù³¶¼º ½Å¿°, ´Ù³¶¼º ½ÅÁúȯ µîÀÌ ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡¿Í »ýȰ½À°üº´ Áõ°¡´Â CKDÀÇ À¯º´·ü Áõ°¡·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¸¸¼ºÄáÆÏº´ Ä¡·áÁ¦´Â Áúº´ÀÇ ÁøÇàÀ» ´ÊÃß°í, ÇÕº´ÁõÀ» Ä¡·áÇϸç, ½ÅÀå ÀüüÀÇ °Ç°­À» À¯ÁöÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å°è ¾ïÁ¦Á¦, Ä®½· ä³Î Â÷´ÜÁ¦, ÀûÇ÷±¸ Á¶Ç÷ ÃËÁøÁ¦, ÀÌ´¢Á¦ µîÀÌ ¸¸¼ºÄáÆÏº´ °ü¸®¿¡ »ç¿ëµÇ´Â ÁÖ¿ä ¾àÁ¦±ºÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ¸¸¼º ½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº ´ç´¢º´°ú °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸ÍÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é 2021³â¿¡´Â Àü ¼¼°è¿¡¼­ ¾à 5¾ï 3,700¸¸ ¸íÀÇ ¼ºÀÎÀÌ ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ ¼öÄ¡´Â 2030³â¿¡´Â 6¾ï 4,300¸¸ ¸í, 2045³â¿¡´Â 7¾ï 8,300¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °íÇ÷¾Ðµµ CKDÀÇ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ½ÅÀåÁúȯÀÇ Á¶±â Áø´Ü°ú Ä¡·á¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½Å¾à ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í Àå±â Ä¡·á¿¡ µû¸¥ ½É°¢ÇÑ ºÎÀÛ¿ëÀÇ À§ÇèÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. º´¿ë¿ä¹ý ¹× Ç¥ÀûÄ¡·áÁ¦ °³¹ßÀº ¸¸¼º½ÅÀåÁúȯ Ä¡·áÁ¦ Á¦Á¶¾÷ü¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ¸¸¼º½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ¸¸¼º½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷Àº Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.°¡ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ¸¸¼º ½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¸¸¼º½ÅÀåÁúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀåÀÇ Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ ¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ ¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀå, ÀûÀÀÁõº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ ¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ ¸¸¼º ½ÅÀ庴 Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Chronic Kidney Disease Drugs Market is estimated to be valued at USD 15.92 Bn in 2025 and is expected to reach USD 23.02 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 15.92 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.40% 2032 Value Projection: USD 23.02 Bn
Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2025
Chronic Kidney Disease Drugs Market - IMG1

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2020-2032, (USD Bn)

5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2020-2032, (USD Bn)

6. Global Chronic Kidney Disease Drugs Market, By Indication, 2020-2032, (USD Bn)

7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)

8. Global Chronic Kidney Disease Drugs Market, By Region, 2020 - 2032, (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â